SymbolRGEN
NameREPLIGEN CORP
SectorHEALTH CARE
RegionNorth America
IndustryBiological Products, (No Diagnostic Substances)
Address41 SEYON STREET, WALTHAM, MA 02453
Telephone7814499560
Fax
Email
Websitehttps://www.repligen.com
IncorporationUNDEFINED
Incorporated On
Employees
Fiscal Year
Public Since
ExchangesNASDAQ
Auditor
Audit StatusNOT PROVIDED
Reporting Status
CIK0000730272
Description

Repligen Corp is a global life sciences company. It develops and commercializes innovative bioprocessing technologies and systems that increase efficiencies and flexibility in the process of manufacturing biological drugs. The companys customers include life science companies, global biopharmaceutical companies, and contract manufacturers worldwide. Repligen markets its products globally through a direct commercial organization in the U.S., Europe, and Asia, as well as through strategic partners in select markets. The majority of the companys revenue is generated in North America.

Additional info from NASDAQ:
Repligen Corp is a global life sciences company. It develops and commercializes innovative bioprocessing technologies and systems that increase efficiencies and flexibility in the process of manufacturing biological drugs. The companys customers include life science companies, global biopharmaceutical companies, and contract manufacturers worldwide. Repligen markets its products globally through a direct commercial organization in the U.S., Europe, and Asia, as well as through strategic partners in select markets. The majority of the companys revenue is generated in North America.

2026-08-26 11:30

Repligen Corporation to Present at Wells Fargo 21st Annual Healthcare Conference

Read more
2026-08-21 20:06

Director Loeillot Olivier 🟡 adjusted position in 5.4K shares (1 derivative) of REPLIGEN CORP (RGEN) at $180.00 ($2.5M) Transaction Date: Aug 20, 2026 | Filing ID: 058417

Read more
2026-08-20 15:53

📋 Loeillot Olivier (Officer) plans to sell 5K shares of REPLIGEN CORP (at $180.00 each, total $977K) Filed: Aug 20, 2026 | ID: 006257

Read more
2026-07-28 11:13

(30% Negative) REPLIGEN CORP (RGEN) Reports Q3 2026 Financial Results

Read more
2026-07-28 11:00

Repligen Reports Second Quarter 2026 Financial Results and Updates Full Year 2026 Financial Guidance

Read more
2026-07-22 12:56

(75% Positive) REPLIGEN CORP (RGEN) Announces Business Combination

Read more
2026-07-22 10:04

New Form 425 - REPLIGEN CORP <b>Filed:</b> 2026-07-22 <b>AccNo:</b> 0001193125-26-311411 <b>Size:</b> 2 MB

Read more
2026-07-22 10:00

Repligen to Acquire BioLife Solutions, Expanding Its Cell Therapy Capabilities with Market Leading Biopreservation Media

Read more
2026-07-17 20:40

Garland Jason K 🔴 sold 530 shares of REPLIGEN CORP (RGEN) at $150.00 Transaction Date: Jul 16, 2026 | Filing ID: 307925

Read more
2026-07-16 17:45

📋 Garland Jason K (Officer) plans to sell 530 shares of REPLIGEN CORP (at $150.00 each, total $80K) Filed: Jul 16, 2026 | ID: 005250

Read more